Judge Dismisses Patent Suit Against Amgen

Law360, New York (February 20, 2004, 12:00 AM EST) -- Amgen won a court ruling that threw out a patent challenge to its arthritis treatment Enbrel, one of the biotech company’s best-selling drugs.

U.S. District Judge Gary Klausner of the Central District of California dismissed the lawsuit. He said Yeda Research and Development Co., which licenses inventions of the Weizmann Institute of Science in Israel, is the rightful owner of the patent, not the plaintiff, Israel Bio-Engineering.

He said that any agreement between Israel Bio-Engineering and Yeda expired before the patent was issued, and that Israel...
To view the full article, register now.